{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:29:59Z","timestamp":1791138599944,"version":"4.1.0"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2011,7,27]],"date-time":"2011-07-27T00:00:00Z","timestamp":1311724800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0022739","type":"journal-article","created":{"date-parts":[[2011,7,27]],"date-time":"2011-07-27T21:00:28Z","timestamp":1311800428000},"page":"e22739","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":72,"title":["Synergistic Interactions between HDAC and Sirtuin Inhibitors in Human Leukemia Cells"],"prefix":"10.1371","volume":"6","author":[{"given":"Michele","family":"Cea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora","family":"Soncini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floriana","family":"Fruscione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizzia","family":"Raffaghello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Garuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Emionite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Moran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Magnone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Zoppoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Reverberi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Caffa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Salis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Cagnetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micaela","family":"Bergamaschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Casciaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Pierri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Damonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Ansaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Gobbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Pistoia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Ballestrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Patrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santina","family":"Bruzzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Nencioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2011,7,27]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1200\/JCO.2009.22.1291","article-title":"Histone deacetylase inhibitors in cancer therapy.","volume":"27","author":"AA Lane","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc1779","article-title":"Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer.","volume":"6","author":"S Minucci","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nature08197","article-title":"Recent progress in the biology and physiology of sirtuins.","volume":"460","author":"T Finkel","year":"2009","journal-title":"Nature"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/35001622","article-title":"Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase.","volume":"403","author":"S Imai","year":"2000","journal-title":"Nature"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2004-05-1693","article-title":"A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.","volume":"105","author":"JC Byrd","year":"2005","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2007-10-115873","article-title":"Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.","volume":"112","author":"G Garcia-Manero","year":"2008","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2007-06-098061","article-title":"Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.","volume":"111","author":"G Garcia-Manero","year":"2008","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/cncr.22891","article-title":"Valproic acid for the treatment of myeloid malignancies.","volume":"110","author":"A Kuendgen","year":"2007","journal-title":"Cancer"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"7095","DOI":"10.1158\/1078-0432.CCR-08-1007","article-title":"Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia.","volume":"14","author":"OM Odenike","year":"2008","journal-title":"Clin Cancer Res"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1158\/0008-5472.CAN-08-3365","article-title":"The critical role of the class III histone deacetylase SIRT1 in cancer.","volume":"69","author":"T Liu","year":"2009","journal-title":"Cancer Res"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/sj.leu.2403910","article-title":"Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors.","volume":"19","author":"CA Bradbury","year":"2005","journal-title":"Leukemia"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1365-2141.2009.07749.x","article-title":"SIRT1 is downregulated during neutrophil differentiation of acute promyelocytic leukaemia cells.","volume":"146","author":"J Wampfler","year":"2009","journal-title":"Br J Haematol"},{"key":"ref13","article-title":"Nicotinamide Blocks Proliferation and Induces Apoptosis of Chronic Lymphocytic Leukemia Cells through Activation of the p53\/miR-34a\/SIRT1 Tumor Suppressor Network.","author":"V Audrito","year":"2011","journal-title":"Cancer Res"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1093\/emboj\/21.10.2383","article-title":"Human SIR2 deacetylates p53 and antagonizes PML\/p53-induced cellular senescence.","volume":"21","author":"E Langley","year":"2002","journal-title":"EMBO J"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1124\/jpet.107.124461","article-title":"Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors.","volume":"322","author":"SM Lee","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0092-8674(01)00524-4","article-title":"Negative control of p53 by Sir2alpha promotes cell survival under stress.","volume":"107","author":"J Luo","year":"2001","journal-title":"Cell"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0092-8674(01)00527-X","article-title":"hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase.","volume":"107","author":"H Vaziri","year":"2001","journal-title":"Cell"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1146\/annurev.pharmtox.45.120403.095825","article-title":"Clinical development of histone deacetylase inhibitors as anticancer agents.","volume":"45","author":"DC Drummond","year":"2005","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1158\/0008-5472.CAN-05-3617","article-title":"Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes.","volume":"66","author":"B Heltweg","year":"2006","journal-title":"Cancer Res"},{"key":"ref20","first-page":"7436","article-title":"FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.","volume":"63","author":"M Hasmann","year":"2003","journal-title":"Cancer Res"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12013-008-9041-4","article-title":"The NAD World: a new systemic regulatory network for metabolism and aging\u2013Sirt1, systemic NAD biosynthesis, and their importance.","volume":"53","author":"S Imai","year":"2009","journal-title":"Cell Biochem Biophys"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1126\/science.1171641","article-title":"Circadian clock feedback cycle through NAMPT-mediated NAD+ biosynthesis.","volume":"324","author":"KM Ramsey","year":"2009","journal-title":"Science"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nm.1913","article-title":"NAMPT is essential for the G-CSF-induced myeloid differentiation via a NAD(+)-sirtuin-1-dependent pathway.","volume":"15","author":"J Skokowa","year":"2009","journal-title":"Nat Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nm.1906","article-title":"Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuin-dependent manner.","volume":"15","author":"F Van Gool","year":"2009","journal-title":"Nat Med"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"e7897","DOI":"10.1371\/journal.pone.0007897","article-title":"Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE.","volume":"4","author":"S Bruzzone","year":"2009","journal-title":"PLoS One"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1128\/MCB.26.1.28-38.2006","article-title":"Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage.","volume":"26","author":"JM Solomon","year":"2006","journal-title":"Mol Cell Biol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2141.2008.07426.x","article-title":"Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells.","volume":"144","author":"AB Bouzar","year":"2009","journal-title":"Br J Haematol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.","volume":"22","author":"TC Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0092-8674(04)00046-7","article-title":"Cell death: critical control points.","volume":"116","author":"NN Danial","year":"2004","journal-title":"Cell"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1126\/science.1099196","article-title":"Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase.","volume":"305","author":"HY Cohen","year":"2004","journal-title":"Science"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1002\/art.24864","article-title":"SIRT1 regulation of apoptosis of human chondrocytes.","volume":"60","author":"K Takayama","year":"2009","journal-title":"Arthritis Rheum"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"5394","DOI":"10.1158\/0008-5472.CAN-05-3835","article-title":"Potent in vivo anti-breast cancer activity of IN-2001, a novel inhibitor of histone deacetylase, in MMTV\/c-Neu mice.","volume":"66","author":"KE Joung","year":"2006","journal-title":"Cancer Res"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1158\/1535-7163.425.3.4","article-title":"The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells.","volume":"3","author":"XD Zhang","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1007\/s10495-006-0283-6","article-title":"Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells.","volume":"11","author":"S Gillespie","year":"2006","journal-title":"Apoptosis"},{"key":"ref35","article-title":"NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response.","author":"B Wang","year":"2010","journal-title":"Oncogene"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s10637-007-9083-2","article-title":"The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor.","volume":"26","author":"K Holen","year":"2008","journal-title":"Invest New Drugs"},{"key":"ref37","article-title":"Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data.","author":"A von Heideman","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"6035","DOI":"10.1182\/blood-2009-03-209213","article-title":"APO866 activity in hematologic malignancies: a preclinical in vitro study.","volume":"113","author":"M Cea","year":"2009","journal-title":"Blood"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2008-08-173369","article-title":"The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies.","volume":"113","author":"A Nahimana","year":"2009","journal-title":"Blood"},{"key":"ref40","first-page":"963","article-title":"Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.","volume":"8","author":"SD Gore","year":"2002","journal-title":"Clin Cancer Res"},{"key":"ref41","first-page":"3578","article-title":"Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.","volume":"9","author":"WK Kelly","year":"2003","journal-title":"Clin Cancer Res"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1042\/bj3610379","article-title":"A novel cycling assay for cellular cADP-ribose with nanomolar sensitivity.","volume":"361","author":"R Graeff","year":"2002","journal-title":"Biochem J"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0022739","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T12:16:16Z","timestamp":1686226576000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0022739"}},"subtitle":[],"editor":[{"given":"Ben C. B.","family":"Ko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,7,27]]},"references-count":42,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2011,7,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0022739","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,27]]}}}